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Introduction
Head and neck paragangliomas (HNPGL) are neuroendocrine
tumors that arise from paraganglionic tissue associated with
the parasympathetic nervous system. The most common
location is the carotid body, other locations include the vagal,
jugular, tympanic, and aortic bodies. Paragangliomas are often
hereditary, in the Netherlands mutations in subunit-D of the
succinate dehydrogenase (SDH) gene are themost common.1–3
Mutations in this gene are associated with the occurrence of
multiple head and neck paragangliomas, occasional pheochro-
mocytomas, and a very low frequency of malignant transfor-
mation.4,5 Surgical resection is the primary treatment of head
and neck paragangliomas, but radiotherapy may also be used
to gain local control of the disease. However, head and neck
paragangliomas generally show a very favorable natural
course, and surgery carries a high risk of cranial nerve impair-










Abstract Objective Treatment for head and neck paragangliomas (HNGPL) can be more
harmful than the disease. After diagnosis, an initial period of surveillance is often
indicated, and surgery or radiotherapy is reserved for progressive disease. With the aim
to optimize this “wait and scan” strategy, we studied growth and possible predictors.
Design A retrospective cohort study was conducted.
Setting This study was conducted at a tertiary referral center for patients with HNGPL.
Methods Tumor volume was estimated for 184 SDHD-related carotid and vagal body
paragangliomas using sequential magnetic resonance imaging. Cox regression was
used to study predictors of tumor growth.
Results The estimated fraction of growing tumors ranged from 0.42 after 1 year of
follow-up to 0.85 after 11 years. A median growth rate of 10.4 and 12.0% per year was
observed for carotid and vagal body tumors, respectively. Tumor location, initial volume,
and age (p < 0.05) were included in our prediction model. The probability of growth
decreased with increasing age and volume, indicating a decelerating growth pattern.
Conclusions We created a prediction model (available online), enabling a more
individualized “wait and scan” strategy. The favorable natural course of carotid and
vagal body paragangliomas was confirmed; although with long follow-up growth will
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Therefore, await and scanpolicy is oftenadopted.6–12With the
introduction of presymptomatic testing for causative genes, an
increasing number of small paragangliomas is detected. For
these asymptomatic tumors with no recorded growth, obser-
vation may be the best management initially.13 Surgical or
radiation therapymust be considered if evident growth occurs
or if the tumor causes debilitating symptoms. To optimize this
treatment strategy and further improve counseling of patients
and their families, knowledge of the likelihood of (rapid)
progression is essential. The natural course of head and neck
paragangliomas was addressed in five case series.6–9,14 All
concluded that many paragangliomas (30–65%) remain stable
and if progression is observed, growth is very slow.6–9,14
However, predictors remain to be determined. Also, we re-
centlydefinednewcutoff points forgrowth in thecarotid (10%)
and vagal (25%) body tumors enabling more accurate estima-
tion of tumor progression.15 On a cohort of 184 SDHD-related
head and neck paragangliomas, we studied growth rate and




of the Leiden University Medical Center was used to identify
carriers of an SDHD germlinemutation. Subjects with a carrier
status confirmed bymolecular genetic testing aswell as family
members affected with paragangliomas (obligate carriers)
were both eligible for inclusion if diagnosedwith paraganglio-
mas between January 2002 and October 2015. SDHD germline
mutation carriers with the carotid body and/or vagal body
paragangliomas managed with primary observation, and at
least two digital available magnetic resonance imaging (MRI)
scans of the head and neck regionwere selected.MRI scans are
digitally available since 2002, to prevent selection bias, only
subjects diagnosed since January 2002 were eligible for inclu-
sion. Jugulotympanic tumors were not included as we pre-
viously described that it was difficult tomeasure these tumors
consistently.15 Conglomerates of carotid and vagal body para-
gangliomasweremeasured as two separate tumors if possible,
and otherwise excluded (►Fig. 1). The date of thefirst digitally
available MRI was considered the date of inclusion and time
between the first and most recent digitally available MRI scan
was considered the follow-up time. Relevant clinical para-
meters were retrieved from medical records.
According to the Dutch law, approval of the institutional
ethics committee was not required, because all data used,
were collected for routine patient care.
Volume Estimation
At our institution, MRI is used as a diagnostic tool and for
follow-up of patients with head and neck paragangliomas.
Examinations were performed on 1.5T and 3T scans. Volume
was estimated at the first (T1) and most recent (T2) digitally
available MRI, on the contrast enhanced three-dimensional
time of flight MR angiography sequence.15,16 Three perpen-
dicular dimensions were used to calculate tumor volume,
assuming an ellipsoid shape (►Fig. 2).
Volume (V) ¼ 4/3π (½ A  ½ B  ½ C)
All measurements were performed by two observers
(B.L.H. and L.M.H.P.). If measurements at the same time point
differed more than the previously determined smallest
detectable difference (10% for carotid body and 25% for vagal
body paragangliomas), the consensus was reached.15 Other-
wise, the mean of both measurements was used for further
calculations. Subsequently, growth rate was calculated,
Growth rate (cm3/y) ¼ (V2  V1)/(T2  T1)
Growth rate (%/y) ¼ ([V2  V1]/[T2  T1])/V1
with V1 being the estimated volume at T1 and V2 being
the estimated volume at T2.
Statistics
The Statistical Package for Social Sciences (IBM SPSS Statistics,
Version 23.0, Armonk, New York, United States) and R version
3.2.5 were used for statistical analysis.17 The Kaplan–Meier
product limit estimator provided the estimated fraction of
growing tumors and themedian time to grow. Coxproportional
hazards regression with grouped jackknife variance estimator,
to account for dependence among tumors from the same
patient, was used to assess the relationship between possible
predictors andgrowth.18Todifferentiategrowth frommeasure-
ment error, growthwas defined as a volume increase of at least
10% for carotid body and 25% for vagal body tumors.15 If a
Fig. 1 Carotid and vagal body paragangliomas included in this study.
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regression or progression less than the applicable cutoff value
wasobserved, the censoring timewasequal to follow-uptime. If
growth was observed, linear growth between T1 and T2 was
assumed and time to growth (i.e., time to a volume increase of
10 or 25%) was calculated.19 Age at inclusion, sex, mutation
(p.Asp92Tyr versus other mutations in SDHD), initial volume
(V1), tumor location (carotid vs. vagal body paragangliomas)
and whether a tumor was symptomatic or asymptomatic at its
diagnosis, were considered possible predictors. Initial volume
was positively skewed, and therefore log2 transformed, also
natural cubic splines (df ¼ 3)wereused to relax theassumption
of linearity. The proportional hazards assumptionwas checked,
usingscaledSchoenfeldresiduals.Toappraisethediscriminative
capability and predictive value, time-dependent receiver oper-
ating characteristic curves (method: nearest neighbor estima-
tion [NNE], span 0.05) were produced, and calibration plots
(bootstrap cross-validated, with 100 cross-validation steps
drawn with replacement, to prevent overfitting) were gener-
ated.20,21Toassess the relationshipbetweenthedevelopmentof
newsignsor symptomsand initial volume, volume increase and
tumor location, a generalized estimation equation approach
with robust estimator was used to account for within-patient
correlation (exchangeable correlationmatrix). Volume increase
(cm3) was positively skewed and for that reason categorized.
Growth rate (%/year) of carotid and vagal body tumors, as well
as, the initial volumeof symptomatic andasymptomatic tumors
were compared with a Mann–Whitney U Test. Statistical sig-
nificance was considered for p values < 0.05. Continuous data
are expressed asmean  standard deviation if the data follows
anormal distribution, if not, themedian and interquartile range
(IQR) are given unless stated otherwise.
Results
Subjects
A total of 184 paragangliomas, 118 carotid body tumors, and
66 vagal body tumors, diagnosed in 103 SDHD germline
mutation carriers were included (►Fig. 1). Overall, 64
(62%) subjects were males, and the median age at inclusion
was 37 (range: 13–62) years. The majority (80%) carried the
c.274G > T, p.Asp92Tyr Dutch founder mutation, the re-
maining 21 subjects carried other previously described
germline mutations in SDHD.
Growth Characteristics
In a median follow-up time of 4.7 (IQR: 2.6; 6.3) years,
growth was observed in 75% of the carotid body and 64%
of vagal body paragangliomas. Regression was observed in
5%; the remaining tumors were stable. The median growth
rate was 10.4%/y for carotid body and 12.0%/y for vagal body
tumors (p ¼ 0.51). If only growing tumors were considered,
the median growth rate increased to 15.1 and 21.3%/y, for
carotid and vagal body tumors, respectively, corresponding
to a tumor doubling time of 5.9 and 4.7 years (►Table 1). The
median time to growth was 1.4 (IQR: 0.5; 5.1) years, and the
estimated fraction of growing tumors was 0.42 (95% con-
fidence interval [CI]: 0.35; 0.49) 1 year after inclusion and
increased to 0.85 (95% CI: 0.70; 0.92) after 11 years (►Fig. 3).
Overall, 52 tumors were classified as clinically detected,
with a lateral neck mass being the most reported symptom.
Cranial nerve impairment attributable to tumor progression
was observed in nine cases (4.9%), of which one developed
during follow-up. The vagus nerve was affected most often.
At the date of inclusion, 32% of the carotid body and 27% of
vagal body tumorswere symptomatic. Themedian volume of
symptomatic tumorswas substantially larger comparedwith
asymptomatic tumors, 15.2 cm3 (IQR: 6.4; 24.3) versus
1.9 cm3 (IQR: 0.7; 4.9, p < 0.001).
Clinical progression, defined as the progression of existing
or development of new signs or symptoms, was reported in
66 cases (35.9%). In 45 cases new signs or symptoms were
recorded, while in the remaining 21 cases it concerned
progression of existing signs or symptoms. In most cases, it
concerned the detection of a neck mass or progression of a
Fig. 2 (a) A shows the largest diameter in the axial plane and B shows the diameter perpendicular to A. (b) C shows the largest craniocaudal
diameter, and was measured in sagittal or coronal slices.
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preexisting swelling. Other signs or symptoms, including
medial bulging of the lateral pharynx wall, pain or discom-
fort, and dysphagia, were reported less often. There was a
statistically significant relationship between initial volume
and the development of new signs or symptoms (odds ratio:
1.23, p ¼ 0.04). With increasing volume expansion, new
signs or symptoms were reported more often, although
this relation was not statistically significant (odds ratio:
1.21, p ¼ 0.07) (►Supplementary Table 1 online-only). A
total of 19 (10%) tumors (13 carotid and 6 vagal body tumors)
were treated after T2. Conservativemanagement wasmainly
(74%) discontinued because of evident progression. In the
remaining cases, patients’ preference was the most impor-
tant reason for the switch to active treatment.
Predictors
At univariate and multivariate analysis tumor location, initial
tumor volume (log2 transformed) and age at inclusion were
statistically significant predictors of growth, and were thus
includedinourpredictionmodel (►Table 2). Thehazard ratioof
age was constant over time. This was however not true for
carotidversusvagalbodytumors. Therefore, tumorlocationwas
included in our predictionmodel as a stratification factor. Also,
volumewas nonproportional, but only for values between 0.03
and 1.58 cm3 (boundary to first internal knot), the associated
parameter estimate was interpreted as an average effect.22
Prediction of Growth
The predictedprobabilityof growthdecreasedwith increasing
ageandvolume, increasedover timeandwashigher forcarotid
body tumors compared with vagal body tumors (►Fig. 4). For
instance, if growthwas predicted for a patient of 60 yearswith
Table 1 Growth characteristics and descriptives for CBT and VBT
CBT VBT
Median/N IQR/% Median/N IQR/%
All 118 66
Male 73 62% 42 64%
c.274G> T (p.Asp92Tyr) 89 75% 52 79%
Screening detected 82 69% 50 76%
Age (y) 37 30–50 40 30–51
Volume (cm3) 3.0 0.9–9.3 3.8 1.2–16.8
Growth rate (cm3/y) 0.26 0.05–0.76 0.41 0.08–1.46
Growth rate (%/y) 10.4 3.0–22.7 12.0 3.6–27.7
Growth 88 75% 42 64%
Male 55 62% 27 64%
c.274G> T (p.Asp92Tyr) 67 76% 33 79%
Screening detected 62 70% 32 76%
Age (y) 37 30–50 38 30–47
Volume (cm3) 2.5 0.8–8.1 3.8 1.1–11.3
Growth rate (cm3/y) 0.35 0.18–1.17 0.72 0.27–1.97
Growth rate (%/year) 15.1 6.8–30.0 21.3 12.3–35.3
Td (y) 5.9 3.5–11.2 4.7 3.6–7.3
Stable 22 19% 23 35%
Regression 8 7% 1 2%
Abbreviations: CBT, carotid body tumors; IQR, interquartile range; Td, tumor doubling time (years); VBT, vagal body tumors.
Fig. 3 The cumulative proportion of growing tumors over time, with
95% confidence interval and numbers at risk.
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a carotid body tumor of 15 cm3, the predicted probability of
growth (volume increase to at least 16.5 cm3) was 32% after
1 year of follow-up, 49% after 2 years, and increased to 60%
after 5 years (►Supplementary Fig. 1a online-only). In com-
parison, for a patient of 20 years with a carotid body tumor of
5 cm3, the predicted probability of growth (volume increase to
at least 5.5 cm3) was 59, 78, and 88%, respectively (an inter-
active version of the model is available at https://hnpgl.shi-
nyapps.io/growth/) (►Supplementary Fig. 1b online-only).
Model Performance
Median predicted probabilities were 35% (range: 15–97%) for
nongrowing tumors and 51% (range: 17–92%) for growing
tumors after the first year of follow-up, corresponding to an
area under the curve (AUC) of 0.71. After 3 years of follow-up
themedianpredictedprobabilitieswere72%(range: 41–100%)
and 60% (42–92%) for growing and nongrowing tumors,
respectively (AUC: 0.64) (►Fig. 5a, b). The observed and
predicted growth probabilities were approximately equal
for the IQR, the first 2 years of follow-up but diminished after
that (►Fig. 5d–f).
Cut Offs for the Predicted Probability of Growth
The consequences of using different cutoff values to make an
MRI scan after 1 year of follow-up, with respect to scan
reduction as well as number and characteristics of detected
and missed growth are shown in ►Table 3. A similar table
with cutoffs for predicted probability after 2 years is pro-
vided in the supplementary data (►Supplementary Table 2
online-only). If instead of screening all cases after 1 year, a
scanwould only bemade if the predicted probability is equal
to or higher than 34% (corresponding with a sensitivity of
80%), the number of scans would be reduced by 36%. By
subsequently using 40% as a cutoff value tomake anMRI after
2 years (►Fig. 6), the detection of growth would be delayed
with 1 year in 19 cases (17%) and with 2 years in only one
case (0.9%). Fast progression, defined as growth of more than
50%/y, was observed in a total of 19 cases and would be
detectedwith 1-year delay in three (16%) cases (►Table 3 and
►Supplementary Table 3 online-only).
Discussion
This study is the first to use multivariate Cox proportional
hazards regression to examine the growth of head and neck
paragangliomas, and thus factoring in varying follow-up
time.Weused tumor andmeasurement specific cutoff values
for growth, resulting in a more robust estimation of tumor
progression. A perhaps even more significant advantage of
the model mentioned earlier is the possibility to study
predictors. We found a statistically significant effect of
volume, age, and tumor location on the probability of growth
and created a prediction model for growth with fairly good
discrimination and capability to correctly estimate the like-
lihood of growth.
With long follow-up growth is observed in most carotid
and vagal body tumors, with the estimated fraction of
growing tumors ranging from 42% after 1 year of follow-up
to 85% after 11 years. However, with amedian growth rate of
10.4 and 12.0%/y for carotid and vagal body tumors, respec-
tively, progression is slow, especially in comparison with
malignant tumors. In untreated glioblastoma, for instance, a
median growth rate of 1.4%/d was observed.23 Furthermore,
cranial nerve impairment was reported in only one case,
underlining the indolent natural course and safety of a “wait
and scan” strategy. Carotid body tumors are measured more
consistently comparedwith vagal body tumors, resulting in a
smaller cutoff value for growth.15 Consequently, the growth
of carotid body tumors was observed earlier during follow-
up, despite the higher growth rate of vagal body tumors.
Two earlier studies have addressed the growth of carotid
and vagal body tumors; both also concluded that rapid
progression is rare.6,7 Langerman et al reported tumor
growth in only 17 of 47 (38%) paragangliomas, during a
mean follow-up time of 5 years. This relatively small percen-
tage, compared with our results, may be partially explained
by the comparatively high mean age of 56 (range: 17–86)
years. Furthermore, it should be noted that three dimensions
were available in only a limited number of cases and it was
not clear how they differentiated between progressive and
stable tumors. The current results are in agreement with our
prior study, with the variation primarily the result of a
different definition of growth (20 vs. 10 and 25%). Also, the
accuracy of measurements has increased as result of
improved imaging techniques and digital available images
(in our previous study all measurements were performed on
hard copies). Jugulotympanic tumors were not included in
our present study. However, the growth of these tumors (fish
C1–D1) was investigated by Carlson et al.8 They reported
growth, defined as a volume increase of more than 20%, in
42% of tumors during a median follow-up time of 4.8 years.
The relatively high median age of 70 years, may again
partially explain the lower proportion of growing tumors.
Also, the fact that the petrous bone largely surrounds these
tumors may have influenced growth rate as well.





Age at inclusiona,b 0.81 (0.69–0.95) 0.01
Volume log2 transformed
b 0.86 (0.79–0.93) < 0.001
Location (ref ¼ CBT)b,c 0.63 (0.44–0.89) 0.01
p.Asp92Tyr versus other




(ref ¼ screening detected)
1.34 (0.86–2.08) 0.19
Sex (ref ¼ male) 0.97 (0.65–1.46) 0.88
aHazard ratio for a 10-year increase in age.
bIncluded in our prediction model for growth.
cVagal body versus carotid body paragangliomas.
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The decreasing probability of growthwith both increasing
volume and patients age, strongly indicate that paraganglio-
mas exhibit a decelerating growth pattern. Both Gompertz
and logistic models have been used to successfully model
growth of tumors, predominantly in vitro.24 Tumor doubling
time was first introduced by Collins et al to quantify growth
rate and is based on exponential growth.25 Although this
model presumably describes early tumor growth, we antici-
pate that in the long run, a decelerating growth pattern is
more accurate. The calculatedmedian tumor doubling, of 5.9
and 4.7 years for carotid and vagal body tumors, is therefore
likely to be an underestimation of true doubling time.24
Currently, MRI of the head and neck is, at our institution,
generally performed at intervals of 1 to 2 years. Our prediction
model enables a more individualized approach. In addition to
the predictive value of volume, age, and tumor location, these
predictors largely determine treatment possibilities and out-
come, as well as, the decision to switch fromwatchful waiting
to active treatment if tumor growth is observed. Surgery for
small carotid body tumors is relatively safe. However, the risk
of cranial nerve impairment increases with tumor size and is
particularly high (12.5–78.6%) if the tumor surrounds the
carotid vessels. Other complications includepermanent stroke
and hemorrhage, and aremore likely to occur if vascular repair
Fig. 4 With the increasing age and volume, the predicted probability of growth decreases. (a) Displays the relation between age (x-axis) and the
predicted probability of growth after 1 year of follow-up (y-axis). The effect is illustrated for the median volume of carotid and vagal body
paragangliomas (3.0 and 3.8 cm3). The relation between volume (x-axis) and predicted probability (y-axis) is illustrated in (b), and displayed for a
median age of 37 and 40 years for carotid and vagal body tumors, respectively. As shown in (c), the predicted probability of growth increases over
time (displayed for median values of age and volume).
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Fig. 5 Time-dependent (after 1, 2, and 3 years of follow-up) receiver operating characteristics curves (a–c) with the red lines indicating the
1  specificity and the PP associated with a sensitivity of 90%. (d–f) The corresponding calibration plots with the interquartile range (red lines)
and 5th and 95th percentiles (blue dotted lines). AUC, area under the curve; PP, predicted probability.
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is required.26,27 Therefore, surgery should be considered if
growth is observed in a carotid body tumor,whichmay still be
treatedwith lowrisk forcomplications. In comparison, surgery
for vagal body tumors almost inevitably results in functional
loss of the vagus nerve. Therefore, surgery is only advisable if
tumor progression already resulted in lower cranial nerve
impairment, if excessive catecholamine secretion is accom-
panied by symptoms or in the case of malignant disease (i.e.,
the presence of nodal ordistantmetastasis). Radiation therapy
may also be used to gain local control. However, the riskof late
complications, for instance, radiation-inducedmalignancyand
carotid stenosis, should be weighed against the natural
course.27,28Considering the implicationsof tumorprogression
and the likelihood of changing to active treatment if growth is
observed, our prediction model can be used to individualize
screening intervals and thereby reduce the number of “un-
necessary” scans.
It should be noted that although bootstrap cross-validation
was used to prevent overfitting, the model is not (yet)
externally validated. Also, the results presented here may
not apply to sporadic cases. Even though a statistically sig-
nificant differencebetween growth of hereditary and sporadic
cases has previously not been observed, a comparatively lower
growth rate is, considering sporadic HNPGL are on average
diagnosed approximately 15 years later compared with her-
editary cases, plausible.6,8,29 Furthermore, the retrospective















18 99 171 8 (4) 76 1 (1) 19 0 (0)
24 95 150 29 (16) 73 4 (5) 17 2 (11)
28 90 138 41 (23) 70 7 (9) 16 3 (16)
32 85 125 54 (30) 65 12 (16) 16 3 (16)
34 80 115 64 (36) 62 15 (19) 16 3 (16)
37 75 106 73 (41) 59 18 (23) 15 4 (21)
40 70 93 86 (48) 53 24 (31) 15 4 (21)
42 65 86 93 (52) 51 26 (34) 14 5 (26)
46 60 75 104 (58) 47 30 (39) 13 6 (32)
Abbreviation: PP, predicted probability.
aCutoff values for predicted probability.
bAfter 1 year 179 (97%) cases were still under follow-up.
cPercentage of total growth.
dDefined as progression > 50%/y.
ePercentage of total fast progression.
Fig. 6 The screening strategy.
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natureof this study, aswell as themultifocalityassociatedwith
mutations in the SDHD gene, preclude definitive conclusions
regarding clinical progression.
Conclusion
This study, confirms the indolent growth of carotid and vagal
body paragangliomas. We also established the predictive
value of tumor location, volume, and patients’ age. With
increasing age and volume the probability of growth
decreases, indicating a decelerating growth pattern. The
use of these predictors in a model for growth facilitates a
more individualized approach to “watchful waiting.”
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